Literature DB >> 33290476

Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19.

N R Jena1.   

Abstract

Repurposed drugs are now considered as attractive therapeutics against COVID-19. It is shown that Remdesivir, a nucleoside drug that was originally invented for the Ebola virus, is effective in suppressing the replication of SARS-CoV-2 that causes COVID-19. Similarly, Galidesivir, Favipiravir, Ribavirin, N4-hydroxycytidine (EIDD-1931), and EIDD-2801 (a prodrug of EIDD-1931) were also found to be effective against COVID-19. However, the mechanisms of action of these drugs are not yet fully understood. For example, in some experimental studies, these drugs were proposed to act as a RNA-chain terminator, while in other studies, these were proposed to induce base-pair mutations above the error catastrophe limit to stall the replication of the viral RNA. To understand the mutagenic effects of these drugs, the role of different tautomers in their base-pairing abilities is studied here in detail by employing a reliable dispersion-corrected density functional theoretic method. It is found that Remdesivir and Galidesivir can adopt both amino and imino tautomeric conformations to base-pair with RNA bases. While the insertions of G and U are preferred against the amino tautomers of these drugs, the insertion of C is mainly possible against the imino tautomers. However, although Favipiravir and Ribavirin can make stable base pair interactions by using their keto and enol tautomers, the formation of the latter pairs would be less probable due to the endothermic nature of the products. Interestingly, the insertions of all of the RNA bases are found to be possible against the keto tautomer of Favipiravir, while the keto tautomer of Ribavirin has a clear preference for G. Remarkably, due to the negligible difference in the stability of EIDD-2801 and EIDD-1931, these tautomers would coexist in the biological environment. The insertion of G is found to be preferred against EIDD-1931 and the incorporations of U, A, and G are preferred opposite EIDD-2801. These findings suggest that base-pair mutations are the main causes of the antiviral properties of these drugs.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33290476     DOI: 10.1039/d0cp05297c

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  8 in total

Review 1.  Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.

Authors:  Ashley Jia Wen Yip; Zheng Yao Low; Vincent T K Chow; Sunil K Lal
Journal:  Viruses       Date:  2022-06-20       Impact factor: 5.818

Review 2.  Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.

Authors:  Hong Zhou; Wei-Jian Ni; Wei Huang; Zhen Wang; Ming Cai; Yan-Cai Sun
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

3.  Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors.

Authors:  Suyash Pant; N R Jena
Journal:  Eur J Pharm Sci       Date:  2021-09-17       Impact factor: 4.384

Review 4.  RdRp inhibitors and COVID-19: Is molnupiravir a good option?

Authors:  Seyed Mohammad Reza Hashemian; Mohammad Hossein Pourhanifeh; Michael R Hamblin; Mohammad Karim Shahrzad; Hamed Mirzaei
Journal:  Biomed Pharmacother       Date:  2021-12-09       Impact factor: 7.419

5.  Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs.

Authors:  Kieran Maheden; Brendan Todd; Calvin J Gordon; Egor P Tchesnokov; Matthias Götte
Journal:  Enzymes       Date:  2021-10-15

6.  The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review.

Authors:  Lina Kamal; Ahmed Ramadan; Suha Farraj; Lydia Bahig; Sameera Ezzat
Journal:  Saudi Pharm J       Date:  2022-03-10       Impact factor: 4.562

Review 7.  Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.

Authors:  Ikbel Hadj Hassine; Manel Ben M'hadheb; Luis Menéndez-Arias
Journal:  Viruses       Date:  2022-04-18       Impact factor: 5.818

Review 8.  A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.

Authors:  Prerna Malik; Sonika Jain; Pankaj Jain; Jyoti Kumawat; Jaya Dwivedi; Dharma Kishore
Journal:  Arch Pharm (Weinheim)       Date:  2022-01-17       Impact factor: 4.613

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.